Armstrong D K, Hodgman T, Visconti J A, Reilley T E, Garner W L, Dasta J F
Department of Pharmacy, Ohio State University Hospitals, Columbus.
Crit Care Med. 1988 May;16(5):517-20. doi: 10.1097/00003246-198805000-00010.
The clearance of amikacin during hemodialysis (HD) was determined in eight critically ill patients. The dialysis period averaged 3.4 h with a blood flow of 200 ml/min. The average amikacin clearance between dialysis was 7.30 +/- 4.78 (SD) ml/min which increased to 37.5 +/- 8.01 ml/min during dialysis. The average serum amikacin concentration before dialysis fell 27% after dialysis. The fraction of drug in the body removed only from dialysis averaged 21%. Although amikacin was cleared more effectively during HD compared to the interdialysis period, the small amount of drug removed suggests that routine supplemental dosing of amikacin after HD may not be necessary.
在八名重症患者中测定了血液透析(HD)期间阿米卡星的清除率。透析时间平均为3.4小时,血流速度为200毫升/分钟。透析期间阿米卡星的平均清除率为7.30±4.78(标准差)毫升/分钟,透析时增加至37.5±8.01毫升/分钟。透析前的平均血清阿米卡星浓度在透析后下降了27%。仅通过透析从体内清除的药物比例平均为21%。尽管与透析间期相比,HD期间阿米卡星的清除更有效,但清除的药物量较少表明HD后常规补充阿米卡星剂量可能没有必要。